Cognition Therapeutics Inc.
2403 Sidney Street
Suite 261
Pittsburgh
Pennsylvania
15203
United States
Tel: 412-481-2210
Fax: 412-481-2216
Website: http://www.cogrx.com/
Email: info@cogrx.com
46 articles with Cognition Therapeutics Inc.
-
Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation
11/30/2021
Cognition Therapeutics, Inc. will hold a virtual R&D symposium on December 7, 2021, from 10:00am – 12:00pm ET.
-
Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
11/18/2021
Cognition Therapeutics, Inc. today reported consolidated financial results for the third quarter ended September 30, 2021.
-
Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering
11/15/2021
Cognition Therapeutics, Inc. announced the closing of an additional 565,217 shares of its common stock following the exercise in full of the underwriters’ over-allotment option in connection with Cognition’s initial public offering.
-
Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone
11/3/2021
Cognition Therapeutics, Inc. today announced the addition of Ellen B. Richstone to the company’s board of directors
-
Money on the Move: October 6 – 12
10/13/2021
Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week. -
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
-
Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
-
Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering
10/8/2021
Cognition Therapeutics, Inc. today announced the pricing of its upsized initial public offering of 3,768,116 shares of its common stock at a public offering price of $12.00 per share.
-
Cognition Therapeutics Announces Launch of its Initial Public Offering
10/4/2021
Cognition Therapeutics, Inc. today announced that it has launched an initial public offering of 3,350,000 shares of its common stock.
-
Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board
4/20/2021
Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat degenerative disorders by regulating cellular damage response pathways, announced that the board of directors has elected Jack A. Khattar chairman of the board. Mr. Khattar, the founder and CEO of Supernus Pharmaceuticals, was appointed in 2020 to serve as a member of the Cognition board of directors. He replaces former chairman, Robert J. Gailus, w
-
Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.
-
Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference
3/3/2021
Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, reported that Lisa Ricciardi and James O’Brien , Cognition’s chief executive and chief financial officers, would be making a company presentation at the annual H.C. Wainwright Global Life Sciences Conference.
-
Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology
2/1/2021
Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, announced that a peer-reviewed manuscript, entitled, “Sigma-2-Receptor Antagonists Rescue Neuronal Dysfunction Induced by Parkinson’s Patient Brain-Derived α-Synuclein,” has been published online in the Journal of Neuroscience Research.
-
Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance
1/5/2021
Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that President and CEO Lisa Ricciardi is participating in the Biotech Showcase™ 2021 conference and providing an on-demand company presentation. In addition, Ms. Ricciardi will be participating in numerous one-on-one meetings during the week of the annual JP Mo
-
Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s DiseaseMutation Validates Cognition Approach to Oligomer Displacement
10/19/2020
Cognition Therapeutics, Inc. , a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower Binding Affinity than Wild-Type Peptide,” has been published online in the Journal of Neurochemistry ( doi:10.1111/jnc.15212 ). It has b
-
Cognition Therapeutics Appoints Industry Veteran Jack Khattar to its Board of Directors
9/9/2020
Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Jack A. Khattar to its board of directors.
-
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812
8/27/2020
Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease
-
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
6/8/2020
Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in indi
-
Cognition Therapeutics Announces Change in Leadership
3/27/2020
Cognition Therapeutics, Inc. , a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Kenneth I. Moch has stepped down as president and chief executive officer to assume an advisory role. Lisa Ricciardi has transitioned from her position on the Cognition Board of Directors to become acting chief executive officer. Mr
-
Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease
3/17/2020
Cognition Therapeutics, Inc. , a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the publication of an article titled, The Clinical Promise of Biomarkers of Synapse Damage or Loss in Alzheimer’s Disease , which reviews the foundational role of synapses in cognitive function and discusses available and experimental b